Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists use clean ticks to sniff out hidden lyme infection

NCT ID NCT01143558

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 9 times

Summary

This study tested whether clean, lab-bred ticks could find leftover Lyme bacteria in people who had been treated with antibiotics. 45 participants, including those with recent or past Lyme disease and healthy volunteers, had ticks placed on their skin for a few days. The goal was to see if this method, called xenodiagnosis, is safe and can detect bacteria that standard tests miss, helping explain why some people continue to have symptoms after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xenodiagnosis using clean laboratory-bred ticks
What this could lead to
If successful, this method could help detect lingering Lyme bacteria, guiding better treatment for patients with persistent symptoms.
What could go wrong
This is a very early, small study focused on testing a diagnostic method, not a treatment. It may not prove useful or safe for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

45 people

The number who actually took part.

Started

Nov 2010

Finished

Dec 2014

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Criteria for the diagnosis of Lyme disease can be found at The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America (4). 1. Patients With EM (N=35), Post Treatment * Age 18 or older * EM diagnosed by the study physician or, with a diagnosis of EM that is thought to be highly likely by the study physician. * Treatment with at least 1 course of antibiotics that fulfills the Infectious Diseases Society of America guidelines for the recommended therapy for Lyme disease. There must be at least 1 month and up to 4 months between the end of the therapy and the study procedures. 2. High C6 Antibody Titer (N=35) * Age 18 or older * Diagnosed with confirmed or probable early or late Lyme disease as per Centers for Disease Control and Prevention (CDC) case definition (http://www.cdc.gov/ncphi/disss.nndss/caseded/lyme disease 2008.htm), have received recommended antibiotic therapy and have a high C6 ELISA titer (index above 3) at least 6 months after therapy. 3. Post Lyme disease syndrome (N=20) * Age 18 or older * Diagnosed with confirmed or probable early or late Lyme disease fulfilling the case definition of Lyme disease by the CDC (http://www.cdc.gov/ncphi/disss.nndss/caseded/lyme disease 2008.htm) * Received recommended antibiotic therapy, with resolution or stabilization of the objective manifestation(s) of Lyme disease. * New complaints of fatigue, paresthesias or dysesthesias, widespread musculoskeletal pain or cognitive difficulties within 6 months of the diagnosis of Lyme disease * Symptoms are persistent or relapsing for at least a 6-month period after completion of antibiotic therapy, causing reduction in previous levels of occupational, educational, social, or personal activities. * No antibiotic therapy active against Lyme disease in the previous 3 months. 4. Patients With EM (N=20), On Treatment * Age 18 or older * EM diagnosed by the study physician and receiving antibiotic therapy for less than 48 hours. 5. Lyme Arthritis (N=10) * Age 18 or older * Lyme arthritis and have not received therapy. 6. Healthy Volunteers (N=30) * Age 18 or older * No history of Lyme disease * Negative whole-cell Borrelia ELISA or C6 ELISA * Living in an endemic area for Lyme disease. EXCLUSION CRITERIA: * History of allergy to surgical tape or Nitex nylon mesh * History of severe reactions to tick bites (granuloma or systemic reactions) * Inability to maintain the dressing for any reason * Currently receiving any antibiotic or having received antibiotics in the last month (3 months for patients with post Lyme disease syndrome and high C6 titer) (except patients with EM on treatment) * Pregnancy or lactation * Unwillingness to use an effective method of birth control for 3 months after tick placement (women of child-bearing potential only) * Not able to understand all of the requirements of the study or unable to give informed consent and/or comply with all aspects of the evaluation. * Investigational therapy during the time of the study and/or in the month prior to signing the informed consent. * Active severe skin disease, uncontrolled diabetes, cancer other than non-melanoma skin cancers, autoimmune disease requiring immunosuppressive therapy, or history of HIV, chronic viral hepatitis, or syphilis. * Oral steroids in the previous 2 weeks (nasal steroids and replacement doses of steroids are not exclusions) * Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study. EXCLUSION FROM SKIN BIOPSY PART OF THE PROTOCOL: * History of forming large thick scars after skin injuries or surgery * History of excessive bleeding after cuts or procedures * Currently taking anticoagulants * History of allergy to lidocaine * Biopsies will not be done on face, neck, scalp, or over the tibia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erythema migrans are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • Tufts University

    Boston, Massachusetts, 01536, United States

  • Yale University

    New Haven, Connecticut, 06510-8005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.